First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology
- 5 December 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 114 (23), 2490-2497
- https://doi.org/10.1161/circulationaha.106.668434
Abstract
Background— Selectivity, titratability, rapidity of onset, and active reversibility are desirable pharmacological properties of anticoagulant therapy administered for acute indications and collecti...Keywords
This publication has 10 references indexed in Scilit:
- A Novel Antidote-Controlled Anticoagulant Reduces Thrombin Generation and Inflammation and Improves Cardiac Function in Cardiopulmonary Bypass SurgeryMolecular Therapy, 2006
- Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 2006
- The measurement and application of thrombin generationBritish Journal of Haematology, 2005
- Aptamers: An Emerging Class of TherapeuticsAnnual Review of Medicine, 2005
- Hemodynamic Changes after Protamine AdministrationAnesthesiology, 2005
- Antidote-mediated control of an anticoagulant aptamer in vivoNature Biotechnology, 2004
- Relationship of Blood Transfusion and Clinical Outcomes in Patients With Acute Coronary SyndromesJAMA, 2004
- Heparin-Induced Thrombocytopenia: Recognition, Treatment, and PreventionChest, 2004
- RNA aptamers as reversible antagonists of coagulation factor IXaNature, 2002
- Specific assays of hemostasis proteins: FibrinogenLa Ricerca in Clinica e in Laboratorio, 1990